Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion;Avaliação dos valores sérico e pleural dos marcadores tumorais CEA, CYFRA21-1 e CA 15-3 em portadores de derrame pleural

Jornal Brasileiro de Pneumologia

Volumn 33, Issue 2, 2007, Pages 185-191

  Wagner, Isabella Coimbra ^a,d   Guimarães, Murilo José De Barros ^b   Da Silva, Lilian Karine Neves ^a   De Melo, Francisco Montenegro ^b   Muniz, Maria Tereza Cartaxo ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d NONE   (Brazil)

Author keywords

Biological tumor marker; CA 15.3; CEA; Cyfra 21.1; Pleural effusion

Indexed keywords

EID: 34848885205     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132007000200013     Document Type: Article

References (32)

1. Light RW. Pleural effusion related to metastatic malignancies. In: Light RW, editor. Pleural Diseases. 4th ed. Philadelphia: Lippincott; 2001.p.108-34.
2. Loddenkemper R. Thoracoscopy-state of the art. Eur Respir J. 1998;11(1):213-21.
3. American Thoracic Society. Management of malignant pleural effusion. Am J Respir Crit Care Med. 2000;162(5):1987-2001.
4. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J. 1997;10(8):1907-13.
5. Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martín C, et al. CEA, CA 15-3 and Cyfra 21-1 in serum and pleural fluid of patients with pleural effusion. Eur Respir J. 1996;9(1):17-23.
6. Gross JL. Marcadores tumorais séricos em pacientes com carcinoma de pulmão não pequenas células [dissertação]. São Paulo: Faculdade de Medicina, Universidade de São Paulo, 1999.
7. Miédougé M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Câncer. 1999;81(6):1059-65.
8. Ferrer JS. Marcadores tumorales em líquido pleural. Arch Bronconeumol. 2000;36(6):295-7.
9. Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer. 2001;34 suppl 2:S65-9.
10. Malkin A. Tumor Makers. In: Tannock I, Hill R, editors. The basic science of oncology.2nd ed. Baskerville: McGraw-Hill;1992.p.196-206.
11. Dejsomritrutai W, Senawong S, Promkiamon B. Diagnostic utility of CYFRA 21-1 in malignant pleural effusion. Respirology. 2001;06(3):213-6.
12. Braga ACO. Estudo do antígeno carcinoembrionário no diagnóstico dos derrames pleurais [dissertação]. Rio de Janeiro: Universidade Federal Fluminense, 1990.
13. Alexander JC, Silverman NA,Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA. 1976;235(18):1975-9
14. Light RW. Pleural effusion. N Engl J Med. 2002;346(25):1971-7
15. Light, RW. A new classification of parapneumonic effusions and empyema. Chest. 1995;108 (02):299-301.
16. Agresti A. An introduction to categorical data analysis. New York: John Wiley & Sons; 1996.
17. Hosmer Jr DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons; 1989.
18. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg. 1995;170(1):69-74.
19. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985; 60(3):158-64.
20. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vilà S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86(08):1488-95.
21. Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumor Biol 2004;25(5-6):276-81.
22. a edição. Rio de Janeiro;2002.
23. Seiscento M, Bombarda S. Tuberculose. In: Vargas FS, Teixeira LR, Marchi E, editores. Derrame Pleural. São Paulo: Roca;2004.p.271-84.
24. Valdés L, Alvarez D, Valle JM, Pose A, San Jose E. The etiology of pleural effusions in area with high incidence of tuberculosis. Chest. 1996;109(01):158-62.
25. Ryu JS, Lee HJ, Cho JH, Han HS, Lee HL. The implication of elevated carcinoembryonic antigen level in pleural fluid of patients with non-malignant pleural effusion. Respirology. 2003;08(4):487-91.
26. Ferrer JS, Muñoz XG, Orriols RM, Light RW, Morell FB. Evolution of idiopathic pleural effusion: a prospective, longterm follow-up stu dy. Chest. 1996; 109(6):1508-13.
27. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer. 2001;31(1):9-16.
28. Villena V, López-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuño-de Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer. 2003;40(3):289-94.
29. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. The Oncologist. 2005;10(7):501-7.
30. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, câncer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126(6):1757-63.
31. Kao C, Hsieh JF, Ho YJ, Tsai SC, Lee JK. Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers. Anticancer Res. 1999;19(5C):4545-6.
32. Cullen KJ, Stevens DP, Frost MA, Mackay IR. Carcinoembryonic antigen (CEA), smoking and cancer in a longitudinal population study. Aust N Z J Med. 1976;6(4):279-83.